...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Cancer causes and control: CCC >Combined effect of oral contraceptive use and hormone replacement therapy on breast cancer risk in postmenopausal women.
【24h】

Combined effect of oral contraceptive use and hormone replacement therapy on breast cancer risk in postmenopausal women.

机译：口服避孕药和激素替代疗法对绝经后妇女患乳腺癌风险的综合影响。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

OBJECTIVE: We examined breast cancer risk related to lifetime exposure to oral contraceptives (OCs) and hormone replacement therapy (HRT) in postmenopausal women. METHODS: The Women's Contraceptive and Reproductive Experiences (CARE) Study was a population-based case-control study that included 1847 postmenopausal women with incident invasive breast cancer, and 1932 control subjects, identified using random digit dialing. RESULTS: 45% of cases and 49% of controls used both OCs and HRT. OC users were not at increased risk regardless of subsequent HRT exposure. HRT users who had used OCs previously did not have a higher risk of breast cancer than women with no exposure to OCs. We observed a negative interaction (p-value: 0.032) of combined hormone replacement therapy (CHRT) and past OC use. The increase in risk with CHRT was stronger in women who had never used OCs in the past (odds ratio: 1.05; 95% confidence interval: 1.01-1.10 per year of exclusive CHRT use) than in women who had used OCs (odds ratio:1.00; 95% confidence interval: 0.97-1.03). CONCLUSIONS: We found no indication that adverse effects of exposure to OCs or HRT appeared only in the presence of the other hormone or were exacerbated by exposure to the other hormone.
机译：目的：我们检查了绝经后妇女终身与口服避孕药（OCs）和激素替代疗法（HRT）接触所致的乳腺癌风险。方法：《妇女避孕和生殖经验（CARE）研究》是一项基于人群的病例对照研究，包括使用随机数字拨号识别的1847名绝经后绝经后乳腺癌的女性和1932例对照受试者。结果：45％的病例和49％的对照同时使用OC和HRT。无论随后的HRT暴露如何，OC用户的风险都没有增加。以前曾使用过OC的HRT用户比没有接触过OC的女性患乳腺癌的风险更高。我们观察到联合激素替代疗法（CHRT）与过去的OC使用之间存在负相关性（p值：0.032）。与过去从未使用过OC的女性相比，过去从未使用过OC的女性的CHRT风险增加更大（几率：1.05; 95％的置信区间：每年CHRT独家使用的1.01-1.10）。 1.00; 95％置信区间：0.97-1.03）。结论：我们没有迹象表明暴露于OCs或HRT的不良反应仅在存在其他激素的情况下出现，或因暴露于其他激素而加剧。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号